title: Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
abstract: The recent introduction of drugs that inhibit angiogenesis or the mTOR has provided new options for the treatment of metastatic renal cell carcinoma, a disease which often has a poor prognosis. Chemotherapy and cytokine therapy are largely ineffective. The 5-year survival rate is under 10%. Everolimus, an immunosuppressive drug widely used for the prevention of allograft rejection and an mTOR inhibitor, is one of the latest drugs undergoing clinical trials in metastatic renal cell carcinoma. It has been tested in patients with progressive disease after therapy with tyrosine kinase receptor inhibitors (sunitinib, sorafenib or both), which interfere with signaling pathways, such as the VEGF pathway. Clinical efficacy results (progression-free survival) for everolimus are promising and the safety profile is good.
authors.affiliation: Department of Medical Oncology, Hôpital Georges Pompidou European Hospital, Paris Descartes University, 20 rue Leblanc, 75015 Paris, France. stephane.oudard@egp.aphp.fr
authors.forename: Stéphane
authors.initials: S
authors.lastname: Oudard
authors.forename: Jacques
authors.initials: J
authors.lastname: Medioni
authors.forename: Jorge
authors.initials: J
authors.lastname: Aylllon
authors.forename: Eduardo
authors.initials: E
authors.lastname: Barrascourt
authors.forename: Reza-Thierry
authors.initials: RT
authors.lastname: Elaidi
authors.forename: José
authors.initials: J
authors.lastname: Balcaceres
authors.forename: Florian
authors.initials: F
authors.lastname: Scotte
mesh_terms: D000818:Animals; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D009362:Neoplasm Metastasis; D011494:Protein Kinases / Q000187:drug effects; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D015996:Survival Rate; D058570:TOR Serine-Threonine Kinases
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus